Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 2/20 | 0.42 |
| ▸ | SYK | P43405 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.35 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16821860 | 0.89 | SCN5A (0.39) | CYP1A2 | |
| SCHEMBL16821879 | 0.88 | ALOX5AP (0.45) | CYP1A2CYP2C9 | |
| SCHEMBL16821869 | 0.86 | SYK (0.41) | SYKALDH1A1MEN1KMT2AKIT | |
| SCHEMBL16821778 | 0.86 | SCN5A (0.42) | ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL16821894 | 0.84 | GRM5 (0.45) | CTSASYKCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL16821763 | 0.81 | CTSA (0.34) | CTSAALDH1A1MEN1KMT2ACRHR1 | |
| SCHEMBL16821844 | 0.80 | SCN5A (0.36) | CTSASYKALDH1A1MEN1KMT2A | |
| SCHEMBL16821907 | 0.80 | CYP17A1 (0.37) | CTSACRHR1KIT | |
| SCHEMBL16821736 | 0.80 | SCN5A (0.38) | SYK | |
| SCHEMBL16821782 | 0.80 | SYK (0.36) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920018-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920018-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920018-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| EP-3092234-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2018-02-14 | — | — | EP | disclosed |
| EP-3092234-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2018-02-14 | — | — | EP | disclosed |
| US-20170088527-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20170088527-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20170088527-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2017-03-30 | — | — | US | disclosed |
| EP-3092234-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2016-11-16 | — | — | EP | disclosed |
| US-20160317504-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-11-03 | — | — | US | disclosed |
| US-20160317504-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-11-03 | — | — | US | disclosed |
| US-20160317504-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9416115-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCINECES, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416115-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCINECES, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416115-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCINECES, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| WO-2015094670-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015094670-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150175560-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150175560-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150175560-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088527-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | CACNA1A, KCNJ2, KCNH2 | CTSA 4079/4885SYK 2154/4885ALDH1A1 2462/4885 |
| US-20150175560-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | CACNA1A, KCNJ2, KCNH2 | CTSA 4079/4885SYK 2154/4885ALDH1A1 2462/4885 |
| US-20160317504-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | CACNA1A, KCNJ2, KCNH2 | CTSA 4079/4885SYK 2154/4885ALDH1A1 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.